Free Trial

Cognition Therapeutics (CGTX) Competitors

Cognition Therapeutics logo
$0.84 -0.02 (-2.51%)
Closing price 04:00 PM Eastern
Extended Trading
$0.84 +0.00 (+0.12%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CGTX vs. ENTA, ACOG, ALEC, GLSI, IMRX, MOLN, THTX, TNYA, LIMN, and IKT

Should you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Enanta Pharmaceuticals (ENTA), Alpha Cognition (ACOG), Alector (ALEC), Greenwich LifeSciences (GLSI), Immuneering (IMRX), Molecular Partners (MOLN), Theratechnologies (THTX), Tenaya Therapeutics (TNYA), Liminatus Pharma (LIMN), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.

Cognition Therapeutics vs. Its Competitors

Cognition Therapeutics (NASDAQ:CGTX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Cognition Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Cognition Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cognition TherapeuticsN/AN/A-$33.97M-$0.74-1.14
Enanta Pharmaceuticals$64.46M2.45-$116.04M-$4.54-1.63

Cognition Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -149.57%. Enanta Pharmaceuticals' return on equity of -79.83% beat Cognition Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cognition TherapeuticsN/A -194.42% -115.14%
Enanta Pharmaceuticals -149.57%-79.83%-26.65%

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 14.4% of Cognition Therapeutics shares are held by insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 2 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 1.45 beat Cognition Therapeutics' score of 0.93 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cognition Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Enanta Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cognition Therapeutics currently has a consensus price target of $2.83, suggesting a potential upside of 237.30%. Enanta Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 143.24%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cognition Therapeutics is more favorable than Enanta Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cognition Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
Enanta Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Cognition Therapeutics beats Enanta Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CGTX vs. The Competition

MetricCognition TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$52.07M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-1.1421.1828.1120.03
Price / SalesN/A337.65460.63103.88
Price / CashN/A43.2336.5559.01
Price / Book2.718.368.655.90
Net Income-$33.97M-$55.19M$3.25B$258.66M
7 Day Performance28.44%5.89%4.20%2.23%
1 Month Performance180.00%17.63%10.83%12.77%
1 Year Performance-60.00%5.10%34.67%19.36%

Cognition Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGTX
Cognition Therapeutics
2.7831 of 5 stars
$0.84
-2.5%
$2.83
+237.3%
-53.2%$52.07MN/A-1.1420
ENTA
Enanta Pharmaceuticals
3.9217 of 5 stars
$7.73
+2.5%
$18.00
+132.9%
-51.1%$161.18M$67.64M-1.70160Positive News
ACOG
Alpha Cognition
1.7311 of 5 stars
$9.98
-0.1%
$20.00
+100.4%
N/A$160.04MN/A-8.32N/APositive News
ALEC
Alector
4.0601 of 5 stars
$1.62
+1.9%
$4.00
+146.9%
-71.7%$158.99M$100.56M-1.29270Positive News
GLSI
Greenwich LifeSciences
2.2011 of 5 stars
$11.76
+1.5%
$39.00
+231.6%
-26.1%$154.94MN/A-9.333High Trading Volume
IMRX
Immuneering
3.1256 of 5 stars
$4.24
+2.7%
$13.25
+212.5%
+247.8%$148.62M$320K-2.1660
MOLN
Molecular Partners
2.6099 of 5 stars
$3.79
+5.4%
$12.00
+216.3%
-38.4%$145.15M$5.65M-1.98180News Coverage
Gap Up
THTX
Theratechnologies
N/A$3.14
flat
N/A+117.2%$144.38M$85.87M-16.53140Positive News
TNYA
Tenaya Therapeutics
3.8258 of 5 stars
$0.86
-2.3%
$6.25
+629.6%
-77.2%$142.68MN/A-0.74110Positive News
LIMN
Liminatus Pharma
N/A$5.58
+3.0%
N/AN/A$141MN/A0.00N/ANews Coverage
Gap Down
IKT
Inhibikase Therapeutics
1.2218 of 5 stars
$1.88
+2.2%
$6.50
+245.7%
+12.8%$139.76MN/A-0.706News Coverage

Related Companies and Tools


This page (NASDAQ:CGTX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners